Parkinson's Disease Trial, Recruiting NCT06838637 Sponsor: Michael Berger Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT06838637
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who live in British Columbia, Canada and have an active provincial medical services plan (MSP)
  • People between 19 and 70 years of age
  • People who have a chronic, non-progressive spinal cord injury with complete motor paralysis at or above the T6 level of the spine, OR people diagnosed with Multiple System Atrophy (parkinsonian type) — a condition affecting the nervous system (confirm with trial site)
  • People who had their spinal cord injury or diagnosis more than 1 year ago, and who have had at least 6 months since any spinal surgery
  • People with a spinal cord injury who meet a specific injury severity classification (AIS A or B), or people with Multiple System Atrophy who experience a significant drop in blood pressure when standing up
  • People who are able and willing to attend all clinic visits and follow all study procedures
  • People who can understand and communicate in English, or who have access to an appropriate interpreter as assessed by the study team
  • People who do not have painful muscle or joint problems, unhealed broken bones, open pressure sores, or active infections that could interfere with testing
  • People whose spinal cord injury-related health issues (such as muscle stiffness) are being stably managed
  • Women who could become pregnant must not be currently pregnant, breastfeeding, or planning to become pregnant, and must have a confirmed negative pregnancy test before the study begins
  • Women who could become pregnant must agree to use effective contraception during the trial and for at least 28 days after the study ends (abstinence is accepted)
  • Men who are sexually active and whose partners could become pregnant must agree to use effective contraception during the trial and for at least 28 days after the study ends
  • People who are willing to provide informed consent to participate

Who may not be able to join:

  • People who depend on a ventilator (breathing machine) to breathe
  • People with significant, unmanaged depression (based on a standard questionnaire score above 15) or ongoing substance misuse
  • People taking any medication or receiving any treatment that the study doctor believes makes participation unsuitable for that person
  • People who have an intrathecal baclofen pump (a device implanted in the spine to deliver muscle relaxant medication)
  • People who have heart, lung, bladder, or kidney disease that is unrelated to their spinal cord injury, or who have kidney swelling (hydronephrosis) or blocking kidney stones
  • People with a serious current health issue that the study doctor believes would negatively affect their ability to participate — examples include active urinary tract infections, a bone condition called heterotopic ossification, recent changes to certain antidepressant medications, severe muscle pain, pressure sores, or unstable diabetes
  • People who have any metal implants (other than dental implants) in the skull, or who have a pacemaker, stimulator, or medication pump in the trunk of the body
  • People who take more than 40mg of Baclofen (a muscle relaxant medication) per day
  • People with severe anaemia or low blood volume, as shown by a blood test taken in the last six months
  • People who are a member of the research team running this trial, or an immediate family member of someone on the team
  • People who have previously had electrode implant surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael J Berger, MD, FRCPC, The University of British Columbia

Phone: 604-675-8856

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Michael Berger
Registry
ClinicalTrials.gov
Start date
15 February 2024
Est. completion
1 April 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Systolic blood pressure (SBP) changes in millimeters of mercury (mmHg) during TSCS; Blood pressure (BP) changes in millimeters of mercury (mmHg) in 24-hrs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov